209 related articles for article (PubMed ID: 28247842)
1. Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.
Gulluoglu S; Sahin M; Tuysuz EC; Yaltirik CK; Kuskucu A; Ozkan F; Sahin F; Ture U; Bayrak OF
Oncol Res; 2017 Aug; 25(7):1177-1188. PubMed ID: 28247842
[TBL] [Abstract][Full Text] [Related]
2. The role of TNF-α in chordoma progression and inflammatory pathways.
Gulluoglu S; Tuysuz EC; Sahin M; Yaltirik CK; Kuskucu A; Ozkan F; Dalan AB; Sahin F; Ture U; Bayrak OF
Cell Oncol (Dordr); 2019 Oct; 42(5):663-677. PubMed ID: 31175552
[TBL] [Abstract][Full Text] [Related]
3. Distinctive role of dysregulated miRNAs in chordoma cancer stem-like cell maintenance.
Tuysuz EC; Gulluoglu S; Yaltirik CK; Ozbey U; Kuskucu A; Çoban EA; Sahin F; Türe U; Bayrak OF
Exp Cell Res; 2019 Jul; 380(1):9-19. PubMed ID: 30951707
[TBL] [Abstract][Full Text] [Related]
4. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
Bian SB; Yang Y; Liang WQ; Zhang KC; Chen L; Zhang ZT
Ann N Y Acad Sci; 2021 Jan; 1484(1):74-89. PubMed ID: 32827446
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cancer stem-like cells in chordoma.
Aydemir E; Bayrak OF; Sahin F; Atalay B; Kose GT; Ozen M; Sevli S; Dalan AB; Yalvac ME; Dogruluk T; Türe U
J Neurosurg; 2012 Apr; 116(4):810-20. PubMed ID: 22283189
[TBL] [Abstract][Full Text] [Related]
6. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M
Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968
[TBL] [Abstract][Full Text] [Related]
7. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
8. Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction.
Yue X; Zhao Y; Zhang C; Li J; Liu Z; Liu J; Hu W
Oncotarget; 2016 Jan; 7(4):3777-90. PubMed ID: 26716902
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
10. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
11. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
12. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
Ostroumov E; Hunter CJ
Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
Zhang Y; Schiff D; Park D; Abounader R
PLoS One; 2014; 9(3):e91546. PubMed ID: 24621885
[TBL] [Abstract][Full Text] [Related]
14. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers.
Yu S; Li Q; Wang Y; Cui Y; Yu Y; Li W; Liu F; Liu T
Exp Cell Res; 2021 Sep; 406(1):112734. PubMed ID: 34265288
[TBL] [Abstract][Full Text] [Related]
16. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma.
Kuphal S; Wallner S; Bosserhoff AK
Exp Mol Pathol; 2013 Oct; 95(2):156-65. PubMed ID: 23831429
[TBL] [Abstract][Full Text] [Related]
17. Expression and Therapeutic Potential of SOX9 in Chordoma.
Chen H; Garbutt CC; Spentzos D; Choy E; Hornicek FJ; Duan Z
Clin Cancer Res; 2017 Sep; 23(17):5176-5186. PubMed ID: 28606919
[No Abstract] [Full Text] [Related]
18. Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3.
Liu B; Lu Y; Li J; Liu Y; Liu J; Wang W
APMIS; 2015 Oct; 123(10):837-46. PubMed ID: 26271643
[TBL] [Abstract][Full Text] [Related]
19. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
20. The molecular aspects of chordoma.
Gulluoglu S; Turksoy O; Kuskucu A; Ture U; Bayrak OF
Neurosurg Rev; 2016 Apr; 39(2):185-96; discussion 196. PubMed ID: 26363792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
